CDXS News and Press, Codexis Inc. From 05/12/22

The following slide deck was published by Codexis, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Codexis, Inc. 2022 Q1 - Results - Earnings Call Presentation

Codexis, Inc. (CDXS) Q1 2022 Earnings Conference Call May 5, 2022, 4:30 PM ET Company Participants John Nicols – President and Chief Executive Officer Ross Taylor – Senior Vice President and Chief Financial Officer Brendan Strong – Investor Relations, Argot Partners Confe...

Codexis press release (NASDAQ:CDXS): Q1 GAAP EPS of -$0.13 beats by $0.06. Revenue of $35.34M (+96.0% Y/Y) beats by $6.76M. For further details see: Codexis GAAP EPS of -$0.13 beats by $0.06, revenue of $35.34M beats by $6.76M

Total Revenue up 96% and Product Revenue up 200% YOY; Product Gross Margin Expands to 72% Reiterating Guidance for 2022, Including Total Revenue of $152 - $158M REDWOOD CITY Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering...

Codexis (NASDAQ:CDXS) is scheduled to announce Q1 earnings results on Thursday, May 5th, after market close. The consensus EPS Estimate is -$0.15 (vs. -$0.14 last year) and the consensus Revenue Estimate is $28.58M (+58.5% Y/Y). Over the last 2 years, CDXS has beaten EPS estimates 6...

REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster presentations highlighting three of the Company’s gene therapy programs using directed evolu...

REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the first quarter of 2022 on Thursday, May 5, 2022, following ...

Codexis (NASDAQ:CDXS) and seq.Well initiates a strategic partnership and investment to accelerate the commercialization of the latter's genomics workflow solutions. seqWell, a developer of transformative library preparation products for demanding genomics applications, plan to collaborate on ...

seqWell raises $7M Series C funding, led by Codexis Current investors Research Corporation Technologies and BroadOak Capital Partners also participated in the round New funding will be used to accelerate the commercialization of seqWell’s genomics workflow solut...

Codexis is a protein engineering company based in the United States that markets its products globally. The protein engineering industry is experiencing rapid growth as increased investment signals great potential for companies operating in the market. Codexis has experienced loss...